Yolia Health

Yolia Health, founded in 2004 and headquartered in the United States, offers a groundbreaking solution for presbyopia, a condition affecting over 135 million people in the US. The company's Treatment for Vision Improvement (TVT) is a non-invasive, self-administered therapy involving customized contact lenses and specially formulated eye drops. After just 3-5 days of treatment, patients can enjoy up to 12 months of improved vision without the need for reading glasses. Yolia's innovation not only corrects presbyopia without compromising distance vision but also enhances both near and distance vision simultaneously, setting it apart from other alternatives. The company secured a substantial $3.00M Series A investment on 01 January 2017 from notable investors including Oxford Bioscience Partners, BioAccel, Carter Wigell, and Alberto Osio. Yolia Health's pioneering approach to vision care positions it as a promising investment opportunity at the intersection of the education and healthcare industries.